Waldencast PLC (NASDAQ:WALD) Short Interest Down 79.2% in August

Posted by Francis Steltz on Aug 28th, 2026

Waldencast PLC (NASDAQ:WALD – Get Free Report) was the target of a large decline in short interest during the month of August. As of August 14th, there was short interest totaling 58,897 shares, a decline of 79.2% from the July 30th total of 282,629 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average daily volume of 225,077 shares, the short-interest ratio is currently 0.3 days.

Waldencast Stock Performance

Shares of NASDAQ WALD traded down $0.01 during trading hours on Friday, reaching $1.35. The stock had a trading volume of 10,718 shares, compared to its average volume of 628,792. The firm has a 50-day moving average of $1.57 and a 200-day moving average of $1.46. The company has a quick ratio of 0.97, a current ratio of 1.70 and a debt-to-equity ratio of 0.29. Waldencast has a fifty-two week low of $0.72 and a fifty-two week high of $3.22.

Institutional Trading of Waldencast

A number of hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. lifted its stake in shares of Waldencast by 12.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 57,702 shares of the company’s stock worth $114,000 after acquiring an additional 6,516 shares during the period. Stoic Point Capital Management LLC lifted its holdings in Waldencast by 17.1% in the first quarter. Stoic Point Capital Management LLC now owns 1,637,010 shares of the company’s stock valued at $1,555,000 after acquiring an additional 239,000 shares during the period. Bank of New York Mellon Corp grew its stake in shares of Waldencast by 11.2% during the 1st quarter. Bank of New York Mellon Corp now owns 106,112 shares of the company’s stock worth $101,000 after purchasing an additional 10,728 shares during the period. Invesco Ltd. acquired a new position in shares of Waldencast during the 2nd quarter worth $26,000. Finally, CIBC Asset Management Inc purchased a new position in shares of Waldencast in the 4th quarter valued at about $46,000. 41.97% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Canaccord Genuity Group raised their price target on Waldencast from $2.00 to $3.00 and gave the company a “buy” rating in a research note on Tuesday, June 2nd. Weiss Ratings raised Waldencast from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, August 17th. Finally, Wall Street Zen upgraded Waldencast to a “hold” rating in a report on Saturday, May 30th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Waldencast has a consensus rating of “Hold” and a consensus price target of $2.33.

Read Our Latest Analysis on WALD

Waldencast Company Profile

(Get Free Report)

Waldencast plc operates in the beauty and wellness business. The company engages in developing, acquiring, accelerating, and scaling various brands. It provides cosmetic, over-the-counter, and prescription products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands; and a Skintrinsiq device for use in facial treatments that is used by physicians' offices, spas, and aestheticians. The company also offers clean makeup products under the Milk Makeup brand. It sells its products to dermatologists, plastic surgeons, and other physicians who focuses on aesthetic and therapeutic skincare, including physicians on site at medical spas, through its direct sales force, as well as through distribution partners.